▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Bolt Biotherapeutics (NASDAQ: BOLT)

$5.53

(-2.1%)

-$0.12

Price as of August 1, 2025, 4:00 p.m. ET

Bolt Biotherapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
BOLT	-62.38%			-99%
S&P	+14.53%	+90.70%	+13.76%	+60%

Bolt Biotherapeutics Company Info

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

News & Analysis

Featured Article

Why Bolt Biotherapeutics Stock Crashed Today

The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.

Keith Speights | Dec 6, 2021

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services